Addex Parkinson’s Product Progressing In Early Clinical Trials

Addex Pharmaceuticals (SWISS: ADXN) announced that it has completed the first part of a two-part Phase I clinical trial to evaluate the newly developed modified release formulation of ADX48621. ADX48621 is scheduled to start a Phase IIa proof of concept study for the treatment of levodopa associated dyskinesia in Parkinson’s disease during the first half of 2009.

More: continued here

Filed under: Parkinson's Disease on October 27th, 2008